Literature DB >> 9882692

Delta9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture.

M Shen1, S A Thayer.   

Abstract

Delta9-tetrahydrocannabinol (Delta9-THC) is the principal psychoactive ingredient in marijuana. We examined the effects of Delta9-THC on glutamatergic synaptic transmission. Reducing the extracellular Mg++ concentration bathing rat hippocampal neurons in culture to 0.1 mM elicited a repetitive pattern of glutamatergic synaptic activity that produced intracellular Ca++ concentration spikes that were measured by indo-1-based microfluorimetry. Delta9-THC produced a concentration-dependent inhibition of spike frequency with an EC50 of 20 +/- 4 nM and a maximal inhibition of 41 +/- 3%. Thus, Delta9-THC was potent, but had low intrinsic activity. Delta9-THC (100 nM) inhibition of spiking was reversed by 300 nM N-piperidino-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-3-pyrazole-carboxamide (SR 141716), indicating that the inhibition was mediated by CB1 cannabinoid receptors. Delta9-THC attenuated the inhibition produced by a full cannabinoid receptor agonist, (+)-[2, 3-dihydro-5-methyl-3-[(4-morpholinyl)methyl]pyrrolo-[1,2,3-de]-1, 4-benzoxazin-6-yl](1-napthalenyl)methanone monomethanesulfonate (Win 55212-2), indicating that Delta9-THC is a partial agonist. The effect of Delta9-THC on synaptic currents was also studied. 6-Cyano-2,3-dihydroxy-7-niroquiinoxaline (CNQX)-sensitive excitatory postsynaptic currents were recorded from cells held at -70 mV in the whole-cell configuration of the patch-clamp and elicited by presynaptic stimulation with an extracellular electrode. Win 55212-2 and Delta9-THC inhibited excitatory postsynaptic current (EPSC) amplitude by 96 +/- 2% and 57 +/- 4%, respectively. Excitatory postsynaptic current amplitude was reduced to 75 +/- 5% in the presence of both drugs, demonstrating that Delta9-THC is a partial agonist. The psychotropic effects of Delta9-THC may result from inhibition of glutamatergic synaptic transmission. The modest physical dependence produced by Delta9-THC as well as its lack of acute toxicity may be due to the ability of the drug to reduce, but not block, excitatory neurotransmission.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9882692     DOI: 10.1124/mol.55.1.8

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  30 in total

Review 1.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

2.  Long-Lasting In Vivo Effects of the Cannabinoid CB1 Antagonist AM6538.

Authors:  Carol A Paronis; Girish R Chopda; Kiran Vemuri; Ani S Zakarian; Alexandros Makriyannis; Jack Bergman
Journal:  J Pharmacol Exp Ther       Date:  2018-01-08       Impact factor: 4.030

3.  AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.

Authors:  Mark D Black; Rachel J Stevens; Nancy Rogacki; Robert E Featherstone; Yaw Senyah; Odessa Giardino; Beth Borowsky; Jeanne Stemmelin; Caroline Cohen; Philippe Pichat; Michal Arad; Segev Barak; Amaya De Levie; Ina Weiner; Guy Griebel; Geoffrey B Varty
Journal:  Psychopharmacology (Berl)       Date:  2010-12-22       Impact factor: 4.530

Review 4.  Enzymatic pathways that regulate endocannabinoid signaling in the nervous system.

Authors:  Kay Ahn; Michele K McKinney; Benjamin F Cravatt
Journal:  Chem Rev       Date:  2008-04-23       Impact factor: 60.622

Review 5.  The acute effects of cannabinoids on memory in humans: a review.

Authors:  Mohini Ranganathan; Deepak Cyril D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2006-09-26       Impact factor: 4.530

6.  Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo.

Authors:  Nicholas A Jones; Andrew J Hill; Imogen Smith; Sarah A Bevan; Claire M Williams; Benjamin J Whalley; Gary J Stephens
Journal:  J Pharmacol Exp Ther       Date:  2009-11-11       Impact factor: 4.030

Review 7.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

Authors:  R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

8.  Δ(9)-Tetrahydrocannabinol acts as a partial agonist/antagonist in mice.

Authors:  Carol A Paronis; Spyros P Nikas; Vidyanand G Shukla; Alexandros Makriyannis
Journal:  Behav Pharmacol       Date:  2012-12       Impact factor: 2.293

9.  Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist.

Authors:  Terry Luk; Wenzhen Jin; Alexander Zvonok; Dai Lu; Xin-Zhong Lin; Charles Chavkin; Alexandros Makriyannis; Ken Mackie
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

Review 10.  Synaptic targets of Δ9-tetrahydrocannabinol in the central nervous system.

Authors:  Alexander F Hoffman; Carl R Lupica
Journal:  Cold Spring Harb Perspect Med       Date:  2013-08-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.